Well-Intentioned, But Can The Improved AAC Work For UK Medtechs?
Executive Summary
The newly enhanced Accelerated Access Collaborative (AAC) promises a more concerted effort to ensure health-care innovations reach end users. On paper, it looks good, but the medtech industry in the UK has seen several worthy efforts along similar lines ultimately amount to little. Health Enterprise East’s Dr. Anne Blackwood is reserving judgment.
You may also be interested in...
UK Plugs Into ‘Golden Period’ For Medtech Innovation
The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.
UK ABHI 2019: Correct Diagnosis Must Be Followed By Appropriate Therapy
The current hiatus in the Brexit debate has left room for other themes of clinical and commercial importance to the UK medtech industry to rise back to the surface of the national debate. The potential value of the Long Term Plan and innovation adoption and spread, among others, will share top billing at the ABHI’s 2019 UK Market Conference, in mid-June.
UK Plan To Speed Access To ‘Cutting-Edge’ Products
Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.